Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer
Open Access
- 12 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (7), 822-828
- https://doi.org/10.1038/sj.bjc.6603345
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatinCancer Chemotherapy and Pharmacology, 2002
- A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancerLung Cancer, 2001
- Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing miceCancer Chemotherapy and Pharmacology, 1999
- Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patientsCancer Chemotherapy and Pharmacology, 1996
- Pharmacokinetics of Cisplatin and Its Monohydrated Complex in HumansJournal of Pharmaceutical Sciences, 1996
- Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissueAnti-Cancer Drugs, 1996
- Determination of gold and platinum in the presence of blood plasma proteins using inductively coupled plasma mass spectrometry with direct injection nebulizationJournal of Analytical Atomic Spectrometry, 1996
- Chemotherapy in non-small cell lung cancerAnnals of Oncology, 1995
- Ototoxicity of low- and moderate-dose cisplatinCancer, 1985
- Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implicationsEuropean Journal of Cancer and Clinical Oncology, 1982